Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar 15;18(1):93.
doi: 10.1186/s12906-018-2159-z.

The mutagenic and antimutagenic activity of Sutherlandia frutescens extracts and marker compounds

Siyabulela S B N Ntuli  1 , Wentzel C A Gelderblom  2 , David R Katerere  3
Affiliations

The mutagenic and antimutagenic activity of Sutherlandia frutescens extracts and marker compounds

Siyabulela S B N Ntuli et al. BMC Complement Altern Med. .

Abstract

Background: Sutherlandia frutescens (L.) R. Br is endemic to Southern Africa where it has been traditionally used for cancer and diabetes. In recent times it has been marketed for its reputed (but not proven) anticancer, antidiabetic and anti-HIV properties. Little is known about the mutagenic and antimutagenic potential of extracts and common marker compounds of Sutherlandia frutescens. Therefore this study aimed to investigate the putative efficacy and possible long-term adverse effects of using this herb.

Methods: Ethylacetate (EA) and 50% Methanol (MeOH) extracts were screened for mutagenic and antimutagenic activity using the Ames assay utilising TA97a, TA98, TA100 and TA102 in the presence and absence of metabolic activation. Four compounds, L-arginine, L-canavanine, GABA and D-pinitol known to occur in sutherlandia were also included. The total polyphenolic content of the both extracts was determined using the Folin-Ciocalteau method and FRAP and ABTS were used to determine the anti-oxidant potential of the extracts.

Results: The extracts and the standards did not show any cytotoxicity except in TA97a. The EA extract exhibited antimutagenicity against all the bacterial strains at all concentrations tested. The MeOH extract showed both pro-mutagenic and antimutagenic activities with 2-acetamidofluorene and aflatoxin B1 in the presence of metabolic activation of TA98 and TA100, respectively. All compounds, except L-canavanine exhibited antimutagenic activity against all strains. L-canavanine, on the other hand showed co-mutagenicity with 9-aminoacridine on TA97a, at all test concentrations. The extracts and pure compounds exhibited their antimutagenic activity in a dose response manner. L-arginine and GABA showed an some antimutagenic response. EA extract had three times the total phenolic content (12.56 μg GE / mg) observed in the MeOH extract. There was correlation between total phenolic content, antioxidant potential and antimutagenicity.

Conclusion: Both extracts exhibited a protective effect, with the EA extract exhibiting greater potency. L-canavanine acted as a co-mutagen in a dose response manner without metabolic activation. It is suggested that the EA extract be priotized for future development work as it showed a better risk profile and activity.

Keywords: Antimutagenic activity; Antioxidant activity; Fabaceae; Mutagenic activity; Promutagenicity; Sutherlandia frutescens; Total polyphenols.

PubMed Disclaimer

Conflict of interest statement

Ethics approval and consent to participate

Not applicable as no animals or human beings were used.

Consent for publication

All the authors have given consent for this publication.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Structures of the pure compounds from S. frutescens
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Mander M, Mander J, Breen C, et al. Promoting the cultivation of indigenous plants for markets: experiences from KwaZulu-Natal, South Africa. In: RRB L, Temu AB, Melnyk M, et al., editors. Domestication and commercialization of non-timber forest products in agroforestry systems: proceedings of an international conference held in Nairobi, Kenya 19-23 February 1996. 1996.
    1. Mander M. Marketing of Indigenous Medicinal Plants in South Africa. A case study in KwaZulu-Natal. Rome: Food and Agricultural Organization of the United Nations; 1998.
    1. van Wyk B-E. An ethnobotanical survey of medicinal plants in the southern Karoo, South Africa. S Afr J Bot. 2008;74:696–704. doi: 10.1016/j.sajb.2008.05.001. - DOI
    1. Elgorashi EE, Taylor JLS, Maes A, van Staden J, De Kimpe N, Verschaeve L. Screening of medicinal plants used in south African traditional medicine for genotoxic effects. Toxicol Lett. 2003;143(2):195–207. doi: 10.1016/S0378-4274(03)00176-0. - DOI - PubMed
    1. Naidoo V, Seier J. Preclinical safety testing of herbal remedies. In: Katerere DR, Luseba D, editors. Ethnoveterinary botanical medicines for animal health. Boca Raton: CRC Press (Taylor and Francis Group); 2010. pp. 69–93.

MeSH terms

LinkOut - more resources